The adenosine system selectively inhibits TLR-mediated TNF-α production in the human newborn

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 1956-1966

  Levy, Ofer ^a,b   Coughlin, Melissa ^a   Cronstein, Bruce N ^c   Roy, Rene M ^a   Desai, Avani ^c   Wessels, Michael R ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A3 RECEPTOR ANTAGONIST; CYCLIC AMP; CYTOKINE; INTERLEUKIN 6; LIPOPEPTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ESCHERICHIA COLI; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; INFECTION SENSITIVITY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MOLECULAR WEIGHT; NEWBORN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UMBILICAL CORD BLOOD; VACCINATION;

EID: 33746214770     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.1956     Document Type: Article

References (66)

1. Klein, J., and J. Remington. 2001. Current concepts of infections of the fetus and newborn infant. In Infectious Diseases of the Fetus and Newborn Infant, 5th Ed. J. Remington and J. Klein, eds. Saunders, Philadelphia, pp. 1-23.
2. Lewis, D. B., and C. B. Wilson. 2001. Developmental immunology, and role of host defenses in fetal and neonatal susceptibility to infection. In Infectious Diseases of the Fetus and Newborn Infant, 5th Ed. J. Remington and J. Klein, eds. W.B. Saunders, Philadelphia, pp. 25-138.
3. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4: 553-564.
4. Lewis, D. B., and W. Tu. 2004. The physiologic immunodeficiency of immaturity. In Immunologic Disorders in Infants and Children, 5th Ed. E. R. Stiehm, H. D. Ochs, and J. A. Winkelstein, eds. Elsevier, Philadelphia, pp. 687-760.
5. Akira, S., and K. Takeda. 2004. Toll-like receptor signaling. Nat. Rev. Immunol. 4: 499-511.
6. Levy, O. 2005. Innate immunity of the human newborn: distinct cytokine responses to LPS and other Toll-like receptor agonists. J. Endotoxin Res. 11: 113-116.
7. Levy, O., K. A. Zarember, R. M. Roy, C. Cywes, P. J. Godowski, and M. R. Wessels. 2004. Selective impairment of Toll-like receptor-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod but preserves response to R-848. J. Immunol. 173: 4627-4634.
8. Akira, S. 2003. Mammalian Toll-like receptors. Curr. Opin. Immunol. 15: 5-11.
9. Hellman, J., J. D. Roberts, Jr., M. M. Tehan, J. E. Allaire, and H. S. Warren. 2002. Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in Gram-negative sepsis and causes inflammation and death in mice. J. Biol. Chem. 277: 14274-14280.
10. Sellati, T. J., D. A. Bouis, R. L. Kitchens, R. P. Darveau, J. Pugin, R. J. Ulevitch, S. C. Gangloff, S. M. Goyert, M. V. Norgard, and J. D. Radolf. 1998. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. J. Immunol. 160: 5455-5464.
11. Bessler, W. G., W. Baier, U. vd Esche, P. Hoffmann, L. Heinevetter, K. H. Wiesmuller, and G. Jung. 1997. Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization. Behring Inst. Mitt. 98: 390-399.
12. Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. Cutting edge: Immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol. 168: 1533-1537.
13. Flo, T. H., O. Halaas, E. Lien, L. Ryan, G. Teti, D. T. Golenbock, A. Sundan, and T. Espevik. 2000. Human Toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J. Immunol 164: 2064-2069.
14. van der Graaf, C. A., M. G. Netea, I. Verschueren, J. W. van der Meer, and B. J. Kullberg. 2005. Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae. Infect. Immun. 73: 7458-7464.
15. Xing, Z., J. Gauldie, G. Cox, H. Baumann, M. Jordana, X. F. Lei, and M. K. Achong. 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101: 311-320.
16. Diehl, S., and M. Rincon. 2002. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39: 531-536.
17. Jones, S. A. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol 175: 3463-3468.
18. Hasko, G., and B. N. Cronstein. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25: 33-39.
19. Linden, J. 2005. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol 67: 1385-1387.
20. Biesert, L., W. Scheuer, and W. G. Bessler. 1987. Interaction of mitogenic bacterial lipoprotein and a synthetic analogue with mouse lymphocytes. Isolation and characterization of binding proteins. Eur. J. Biochem. 162: 651-657.
21. Muhlradt, P. F., M. Kiess, H. Meyer, R. Sussmuth, and G. Jung. 1997. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185: 1951-1958.
22. Levy, O., R. Jean-Jacques, C. Cywes, R. Sisson, K. A. Zarember, P. J. Godowski, J. Christianson, H. K. Guttormsen, M. C. Carroll, A. Nicholson-Weller, and M. R. Wessels. 2003. Critical role of the complement system in group B Streptococcus-induced tumor necrosis factor α release. Infect. Immun. 71: 6344-6353.
23. Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. USA 97: 13766-13771.
24. 21) on growth and TNF-inducing activity of Gram-negative bacteria tested in neonatal cord blood ex vivo. Infect. Immun. 68: 5120-5125.
25. Ralevic, V., and G. Burnstock. 1998. Receptors for purines and pyrimidines. Pharmacol. Rev. 50: 413-492.
26. Gallo-Rodriguez, C., X. D. Ji, N. Melman, B. D. Siegman, L. H. Sanders, J. Orlina, B. Fischer, Q. Pu, M. E. Olah, P. J. van Galen, et al. 1994. Structure-activity relationships of N6-benzyladenosine-5′-uronamides as A3-selective adenosine agonists. J. Med. Chem. 37: 636-646.
27. Jacobson, K. A. 1998. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci. 19: 184-191.
28. Zhou, Q. Y., C. Li, M. E. Olah, R. A. Johnson, G. L. Stiles, and O. Civelli. 1992. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA 89: 7432-7436.
29. Keddie, J. R., S. M. Poucher, G. R. Shaw, R. Brooks, and M. G. Collis. 1996. In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist. Eur. J. Pharmacol. 301: 107-113.
30. Martin, C., M. Leone, X. Viviand, M. L. Ayem, and R. Guieu. 2000. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit. Care Med. 28: 3198-3202.
31. Cronstein, B. N., D. Naime, and E. Ostad. 1993. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92: 2675-2682.
32. van der Poll, T., S. M. Coyle, K. Barbosa, C. C. Braxton, and S. F. Lowry. 1996. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J. Clin. Invest. 97: 713-719.
33. Dooper, M. M., L. Wassink, L. M'Rabet, and Y. M. Graus. 2002. The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. Immunology 107: 152-159.
34. la Sala, A., D. Ferrari, S. Corinti, A. Cavani, F. Di Virgilio, and G. Girolomoni. 2001. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J. Immunol. 166: 1611-1617.
35. Leal-Berumen, I., D. P. Snider, C. Barajas-Lopez, and J. S. Marshall. 1996. Cholera toxin increases IL-6 synthesis and decreases TNF-α production by rat peritoneal mast cells. J. Immunol. 156: 316-321.
36. Soares, M. B., R. G. Titus, C. B. Shoemaker, J. R. David, and M. Bozza. 1998. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-α and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. J. Immunol 160: 1811-1816.
37. Ollivier, V., G. C. Parry, R. R. Cobb, D. de Prost, and N. Mackman. 1996. Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J. Biol. Chem. 271: 20828-20835.
38. Grandjean-Laquerriere, A., R. Le Naour, S. C. Gangloff, and M. Guenounou. 2003. Differential regulation of TNF-α, IL-6 and IL-10 in UVB-irradiated human keratinocytes via cyclic AMP/protein kinase A pathway. Cytokine 23: 138-149.
39. Leal-Berumen, I., D. P. Snider, C. Barajas-Lopez, and J. S. Marshall. 1996. Cholera toxin increases IL-6 synthesis and decreases TNF-α production by rat peritoneal mast cells. J. Immunol. 156: 316-321.
40. Wagner, D. R., A. Combes, C. McTiernan, V. J. Sanders, B. Lemster, and A. M. Feldman. 1998. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-α. Circ. Res. 82: 47-56.
41. Di Virgilio, F., P. Chiozzi, D. Ferrari, S. Falzoni, J. M. Sanz, A. Morelli, M. Torboli, G. Bolognesi, and O. R. Baricordi. 2001. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97: 587-600.
42. Lukashev, D., A. Ohta, S. Apasov, J. F. Chen, and M. Sitkovsky. 2004. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J. Immunol. 173: 21-24.
43. Sajjadi, F. G., K. Takabayashi, A. C. Foster, R. C. Domingo, and G. S. Firestein. 1996. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J. Immunol 156: 3435-3442.
44. Pinhal-Enfield, G., M. Ramanathan, G. Hasko, S. N. Vogel, A. L. Salzman, G. J. Boons, and S. J. Leibovich. 2003. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am. J. Pathol. 163: 711-721.
45. Hasko, G., D. G. Kuhel, J. F. Chen, M. A. Schwarzschild, E. A. Deitch, J. G. Mabley, A. Marton, and C. Szabo. 2000. Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14: 2065-2074.
46. McWhinney, C. D., M. W. Dudley, T. L. Bowlin, N. P. Peet, L. Schook, M. Bradshaw, M. De, D. R. Borcherding, and C. K. Edwards III. 1996. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-α. Eur. J. Pharmacol 310: 209-216.
47. Broussas, M., P. Cornillet-Lefebvre, G. Potron, and P. Nguyen. 2002. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor. Thromb. Haemostasis 88: 123-130.
48. Gomez, G., and M. V. Sitkovsky. 2003. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102: 4472-4478.
49. Rivkees, S. A., Z. Zhao, G. Porter, and C. Turner. 2001. Influences of adenosine on the fetus and newborn. Mol. Genet. Metab. 74: 160-171.
50. Zhao, Z., K. Makaritsis, C. E. Francis, H. Gavras, and K. Ravid. 2000. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim. Biophys. Acta 1500: 280-290.
51. Ralevic, V., and G. Burnstock. 1998. Receptors for purines and pyrimidines. Pharmacol Rev. 50: 413-492.
52. Ezeamuzie, C. I., and E. Philips. 2003. Positive coupling of atypical adenosine A3 receptors on human eosinophils to adenylyl cyclase. Biochem. Biophys. Res. Commun. 300: 712-718.
53. Palmer, T. M., C. A. Harris, J. Coote, and G. L. Stiles. 1997. Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor. Mol. Pharmacol 52: 632-640.
54. Levy, O., E. E. Suter, R. L. Miller, and M. R. Wessels. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood, 10.1182/blood-2005-12-4821.
55. Kurt-Jones, E., J. Belko, C. Yu, P. E. Newburger, J. Wang, M. Chan, D. M. Knipe, and R. W. Finberg. 2005. The role of Toll-like receptors in herpes simplex infection in neonates. J. Infect. Dis. 191: 746-748.
56. Karlsson, H., C. Hessle, and A. Rudin. 2002. Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect. Immun. 70: 6688-6696.
57. Angelone, D. F., M. R. Wessels, M. Coughlin, E. E. Suter, P. Valentini, L. A. Kalish, and O. Levy. 2006. Innate immunity of the human newborn is polarized towards a high ratio of lL-6/TNF-α production in vitro and in vivo. Fed. Res. In press.
58. Raghupathy, R., M. Makhseed, S. El-Shazly, F. Azizieh, R. Farhat, and L. Ashkanani. 2001. Cytokine patterns in maternal blood after premature rupture of membranes. Obstet. Gynecol. 98: 122-126.
59. Yamamoto, M., S. Yamazaki, S. Uematsu, S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Kuwata, O. Takeuchi, K. Takeshige, et al. 2004. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBξ. Nature 430: 218-222.
60. Maguire, M. H., I. Szabo, P. Slegel, and C. R. King. 1992. Determination of concentrations of adenosine and other purines in human term placenta by reversed-phase high-performance liquid chromatography with photodiode-array detection: evidence for pathways of purine metabolism in the placenta. J. Chromatogr. 575: 243-253.
61. Yoneyama, Y., R. Sawa, S. Suzuki, S. Shin, G. G. Power, and T. Araki. 1996. The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Am. J. Obstet. Gynecol. 174: 267-271.
62. Wheeler, C. P., and D. L. Yudilevich. 1988. Transport and metabolism of adenosine in the perfused guinea-pig placenta. J. Physiol. 405: 511-526.
63. Irestedt, L., I. Dahlin, T. Hertzberg, A. Sollevi, and H. Lagercrantz. 1989. Adenosine concentration in umbilical cord blood of newborn infants after vaginal delivery and cesarean section. Pediatr. Res. 26: 106-108.
64. Semeniuk, D. J., R. Boismenu, J. Tam, W. Weissenhofer, and R. A. Murgita. 1995. Evidence that immunosuppression is an intrinsic property of the α-feto-protein molecule. Adv. Exp. Med. Biol. 383: 255-269.
65. Olding, L. B., N. Papadogiannakis, B. Barbieri, and R. A. Murgita. 1997. Suppressive cellular and molecular activities in maternofetal immune interactions; suppressor cell activity, prostaglandins, and α- fetoproteins. Curr. Top. Microbiol. Immunol. 222: 159-187.
66. Prescott, S. L. 2003. Early origins of allergic disease: a review of processes and influences during early immune development. Curr. Opin. Allergy Clin. Immunol. 3: 125-132.